Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

Cancer Cell. 2023 Nov 13;41(11):1838-1840. doi: 10.1016/j.ccell.2023.09.017. Epub 2023 Oct 19.

Abstract

Patients diagnosed with lung cancer (LC) exhibit increased susceptibility to SARS-CoV-2 infection. Rodilla et al. monitor the levels of plasma anti-nucleocapsid antibodies within a cohort of fully vaccinated LC patients and reveal that the actual infection rate is nearly twice the documented rate, indicating a significant prevalence of unreported cases.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Testing
  • COVID-19*
  • Humans
  • Immunologic Tests
  • Lung Neoplasms*
  • Nucleocapsid
  • SARS-CoV-2